These therapies, Semaglutide and Wegovy, represent a significant shift in approaches to treating type 2 diabetes and, increasingly, excess weight. They work as GLP-1 receptor agonists , mimicking the action https://opensocialfactory.com/story26453048/copyright-semaglutide-understanding-the-the-glp-1-movement